Synthetic prostacyclin agonist, ONO1301, enhances endogenous myocardial repair in a hamster model of dilated cardiomyopathy: A promising regenerative therapy for the failing heart  by Ishimaru, Kazuhiko et al.
E
T
/B
S
Evolving Technology/Basic Science Ishimaru et alSynthetic prostacyclin agonist, ONO1301, enhances endogenous
myocardial repair in a hamster model of dilated cardiomyopathy:
A promising regenerative therapy for the failing heartKazuhiko Ishimaru, MD, Shigeru Miyagawa, MD, PhD, Satsuki Fukushima, MD, PhD,
Atsuhiro Saito, PhD, Yoshiki Sakai, PhD, Takayoshi Ueno, MD, PhD, and Yoshiki Sawa, MD, PhDFrom th
of Me
This stu
the M
Techn
Disclosu
PLGA
merci
Receive
public
Address
gery,
565-0
0022-52
Copyrig
http://dx
1516Objectives: Remodeling of the left ventricle (LV) in idiopathic dilated cardiomyopathy (IDCM) is known to be
associated with multiple pathologic changes that endogenous factors, such as hepatocyte growth factor (HGF)
and vascular endothelial growth factor (VEGF), protect against. Although a clinically relevant delivery method
of these factors has not been established, ONO1301, a synthetic prostacyclin agonist, has been shown to upre-
gulate multiple cardioprotective factors, including HGF and VEGF, in vivo. We thus hypothesized that
ONO1301 may reverse LV remodeling in the DCM heart.
Methods: ONO1301 dose-dependently added to the normal human dermal fibroblasts and human coronary ar-
tery smooth muscle cells in vitro, to measure the expression of HGF, VEGF, stromal cell–derived factor (SDF)-1,
and granulocyte-colony stimulating factor (G-CSF), assessed by real-time polymerase chain reaction (PCR) and
enzyme-linked immunosorbent assay. d-Sarcoglycan-deficient J2N-k hamsters, which is an established DCM
model, were treated by epicardial implantation of an atelocollagen sheet with or without ONO1301 immersion
or sham operation.
Results: ONO1301 dose-dependently upregulated expression of these 4 factors in vitro. ONO1301 treatment,
which induced dominant elevation of ONO1301 levels for 2 weeks, significantly preserved cardiac performance
and prolonged survival compared with the other groups. This treatment significantly upregulated expressions of
cardioprotective factors and was associated with increased capillaries, attenuated fibrosis, and upregulation of
a-sarcoglycan in the DCM heart.
Conclusions: ONO1301 atelocollagen-sheet implantation reorganized cytoskeletal proteins, such as a-sarco-
glycan, increased capillaries, reduced fibrosis, and was associated with upregulated expression of multiple
cardioprotective factors, leading to preservation of cardiac performance and prolongation of survival in the
d-sarcoglycan-deficient DCM hamster. (J Thorac Cardiovasc Surg 2013;146:1516-25)Idiopathic dilated cardiomyopathy (IDCM) is one of the
most critical intractable diseases. The etiology and pathol-
ogy of IDCM have therefore been intensively investigated
to explore other treatment options.1 Clinical and functional
progression of IDCM has been shown to be closely corre-
lated with the histopathology, such as apoptosis of cardio-
myocytes, accumulation of fibrotic components, reduction
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The Journal of Thoracic and Cardiovascular Surcytoskeletal proteins. It has been recently suggested that
cell transplantation into the IDCM heart positively modu-
lates cellular behavior of native cardiac fibroblasts and/or
coronary artery smooth muscle cells (CoASMCs), leading
to upregulation of multiple cardioprotective factors in the
heart.2 Inasmuch as cell transplantation is clinically lim-
ited by the cell-culture procedure and the availability of
a cell processing center, cell-free therapy that enhances
cardiac regeneration has long been sought in the clinical
arena.3
Prostacyclin and its analogs have been shown to upregu-
late expressions of various factors, such as hepatic growth
factor (HGF) and vascular endothelial growth factor
(VEGF) in vitro and in vivo.4 Although previously gener-
ated prostacyclin agonists are chemically unstable, being
limited by the delivery method, it has recently been shown
that ONO1301 is a selective prostacyclin receptor (IPR)
agonist having a unique, chemically stable structure, and
polymerization of ONO1301 with polylactic-co-glycolic
acid copolymer (PLGA) to form a microsphere
(ONO1301-MS) upregulates multiple protective factors,
represented by HGF, for 3 to 4 weeks in vivo.5 We thereforegery c December 2013
Abbreviations and Acronyms
CoASMC ¼ coronary artery smooth muscle cell
DCM ¼ dilated cardiomyopathy
Dd/Ds ¼ diastolic/systolic dimensions
EF ¼ ejection fraction
ELISA ¼ enzyme-linked immunosorbent
assay
GAPDH ¼ glyceraldehyde-3-phosphate
dehydrogenase
G-CSF ¼ granulocyte colony stimulating
factor
HCoASMC ¼ human coronary artery smooth
muscle cell
HGF ¼ hepatic growth factor
IPR ¼ prostacyclin receptor
IDCM ¼ idiopathic dilated cardiomyopathy
LV ¼ left ventricular (ventricle)
N group ¼ atelocollagen sheet without
ONO1301
NHDF ¼ normal human dermal fibroblast
O group ¼ atelocollagen sheet containing
ONO1301
PCR ¼ polymerase chain reaction
PLGA ¼ polylactic-co-glycolic acid
copolymer
S group ¼ sham group
SDF-1 ¼ stromal cell–derived factor-1
VEGF ¼ vascular endothelial growth factor
vWF ¼ von Willebrand factor
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IDCM heart might upregulate cardiac protective factors,
leading to histologic and functional reverse left ventricular
(LV) remodeling.
MATERIALS AND METHODS
Experimental procedures related to animal studies were carried out un-
der the approval of the institutional ethics committee. The investigation
conformed to the ‘‘Principles of Laboratory Animal Care’’ formulated by
the National Society for Medical Research and the ‘‘Guide for the Care
and Use of Laboratory Animals’’ (National Institutes of Health Publication
No. 85 to 23, revised 1996). All experimental procedures and evaluations
were performed in a blinded manner.
Cell Culture
Normal human dermal fibroblasts (NHDFs) and human CoASMCs
(HCoASMCs) were purchased from EIDIA Co, Ltd (Tokyo, Japan). The
cells were cultured on 6-well plates with Dulbecco’s modified Eagle’s me-
dium (Sigma-Aldrich, St Louis, Mo) supplemented with 10% fetal bovine
serum (EIDIA) under 5% carbon dioxide. Next, 1- to 1000-nmol/L
ONO1301 (Ono Pharmaceutical, Osaka, Japan), dimethyl sulphoxide
(Sigma-Aldrich) or dibutyryl cyclic adenosine monophosphate (Sigma-Al-
drich) was added to the culture medium for 72 hours, and then the culture
supernatants and cells (n ¼ 6, respectively) were harvested and stored
at 80C.The Journal of Thoracic and CarProcedure of ONO1301-MS Administration to the
Dilated Cardiomyopathy (DCM) Hamster
Male 20-week-old d-sarcoglycan-deficient J2N-k hamsters and J2N-n
normal hamsters were purchased from Japan SLC (Shizuoka, Japan). Inas-
much as human DCM-like histopathologic features and associated func-
tional deterioration develop in J2N-k hamsters, they have been used as
an established IDCMmodel.6 Each hamster underwent left lateral thoracot-
omy under 1.5% isoflurane anesthesia (n¼ 66). Subsequently, ONO-1301
was delivered into the heart using a novel drug delivery system, in which an
atelocollagen sheet (Integran sheet; Koken Co, Ltd, Tokyo, Japan) shaped
‘‘hand-drum’’ containing ONO1301-MS (10 mg/kg) was placed to cover
the entire ventricular free wall (O group, n ¼ 22). Other hamsters under-
went either ONO1301-free atelocollagen sheet implantation in the same
manner (N group, n ¼ 21) or sham operation (S group, n ¼ 23). After
the layered closure, the hamsters were housed in a temperature-
controlled individual cage until spontaneous or scheduled death at 2 or 4
weeks after the operation (n ¼ 5 each).
Measurement of ONO1301 Concentration in the
Plasma and the Ventricular Tissue
Under isoflurane inhalation (5%), venous blood (1 mL) was sampled
from the internal jugular vein, and the ventricle was then excised from the
hamster at day 1 and weeks 1, 2, 4, and 8 after ONO1301 treatment (n ¼ 3
each). The plasma was stored at 80C, and the ventricle was thoroughly
washed and stored at80C. The concentrations of ONO1301 in the plasma
and the ventricle were measured by high-performance liquid chromatogra-
phy with the tandem mass spectrometric (LC/MS/MS) detection.7
Transthoracic Echocardiography
Transthoracic echocardiography was performed using a system equip-
ped with a 12-MHz transducer and SONOS 5500 (Agilent Technologies,
Palo Alto, Calif) under isoflurane inhalation (1%). Diastolic/systolic di-
mensions (Dd/Ds) and ejection fraction (EF) of the LV were measured.8
Histopathology
The heart was excised under isoflurane anesthesia (5%) and immersion-
fixed with ice cold 4% paraformaldehyde. The fixed heart was embedded
with either paraffin or optimal cutting temperature compound (Funakoshi,
Tokyo, Japan) and transversely sliced to generate paraffin or frozen sec-
tions, respectively. The paraffin sections were stained using picrosirius
red or immunohistologically labeled using anti–von Willebrand factor
(vWF) antibody (DAKO, Glostrup, Denmark). Frozen sections (7-mm
thick) were immunohistologically labeled using anti–a-dystroglycan
(clone: VIA4-1; Upstate Biotechnology, Lake Placid, NY), anti–a-sarco-
glycan (clone: Ad1/20A6; Novocastra, Wetzlar, Germany), anti–b-sarco-
glycan (clone: bSarc/5B1; Novocastra), anti-IPR (Abcam, Cambridge,
United Kingdom), or anti–a-actin (Millipore, Billerica, Mass) antibodies.
The sections were then labeled by corresponding AlexaFluor488/594-
conjugated secondary antibodies counterstained with 6-diamidino-2-
phenylindole (DAPI; Life Technologies, Calif). 3,30-Diaminobenzidine
(DAB) staining of IPR was performed using the LSAB2 kit (DAKO).
Fluorescent-labeled sections were viewed under an ECLIPSE TE 200-U
confocal microscope (Nikon, Tokyo, Japan). The percentage of the total
area that was fibrotic, as determined by picrosirius red staining, was calcu-
lated by using a planimetric method with MetaMorph software (Molecular
Device, Osaka, Japan). The number of capillaries per square millimeter
was calculated by the BZ Analyzer (Keyence, Osaka, Japan) and was
counted in 4 high-power fields per section (a total of 10-12 fields/heart).
Real-Time Polymerase Chain Reaction
Total RNAwas isolated from the cultured cells and the free wall of the
LVusing the RNeasy Kit and reverse-transcribed using Omniscript Reversediovascular Surgery c Volume 146, Number 6 1517
TABLE 1. Forward and reverse primers and probe
F-primer R-primer Probe
Human
GAPDH GAA GGT GAA GGT CGG AGT C GAA GAT GGT GAT GGG ATT TC CAA GCT TCC CGT TCT CAG CC
HGF ATG ATG TCC ACG GAAGAG GAGA CAC TCG TAATAG GCC ATC ATA
GTT GA
TGC AAA CAG GTT CTC AAT GTT
TCC CAG C
VEGF GAA GTG GTG AAG TTC ATG GAT
GTC T
CAC ACAGGATGG CTT GAAGAT G TTC CAG GAG TAC CCT GAT GAG
ATC GA
SDF-1 CAT GCC GAT TCT TCG AAA GC CTA CAATCT GAA GGG CAC AGT
TTG
TGT TGC CAG AGC CAA CGT CAA
GCA
G-CSF GCT GTG GCA CAG TGC ACT CT CCC TGGATC TTC CTC ACT TGC TC CCT GCC CCA GAG CTT CCT GCT
CA
Hamster
GAPDH CTG CAC CAC CAC CTG CTTAGC GCC ATG CCA GTG AGC TTC C CTG CAC CAC CAC CTG CTTAGC
HGF AGG TCC CAT GGATCA CAC AGA GCC CTT GTC GGG ATATCT TTC T ACCAGCAGACAC CACACCGGCA
VEGF GCA CTG GAC CCT GGC TTTACT TCATGG GAC TTC TGC TCT CCT T ACC ATG CCA AGT GGT CCC AGG
CT
a-Sarcoglycan AAC TGA AGA GAG ACATGG
CCA CC
CAG TGC TGG TCC AGG ATG AGG CCT CTC TCC ACC TTG CCC ATG
TTC A
b-Sarcoglycan TCC ACT GAG AGG ATTACC AGC
AAT
AGT TTG TAG CGC ACC CAG TCA C TCC TCA ATG GAA CTG TGATGG
TCA GCC C
a-Dystroglycan CACACAGTCATTCCAGCTGTTGT TCATCC AGC TCG TCT GCA AAG CCT TGA GGA CCA GGC CAC CTT
TAT CAA
GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; HGF, hepatic growth factor; VEGF, vascular endothelial growth factor; SDF-1, stromal cell–derived factor-1; G-CSF,
granulocyte colony stimulating factor.
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reaction (PCR) was performed with the ABI 7500 Fast Real-Time PCR us-
ing TaqMan Universal Master Mix (Applied Biosystems, Division of Life
Technologies Corporation, Carlsbad, Calif) and the designed primers/
probes (Table 1). Expression of eachmRNAwas normalized to that of glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH).
Western Blotting
The LV free wall was homogenized and centrifuged at 1000 g at 4C for
10 minutes to retrieve protein. Subsequently, 10 to 20 mg of protein was
subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis
with 12.5% gels and transferred to polyvinylidene difluoride membranes
(GE Healthcare, Little Chalfont, United Kingdom) using the Mini Trans-
Blot system (170-3930; Bio-Rad Laboratories, Hercules, Calif). Protein
blots in polyvinylidene difluoride membranes were incubated with each
of the primary antibodies against a-sarcoglycan or GAPDH (Abcam,
Plc, Cambridge, United Kingdom). The membranes were incubated with
the corresponding horseradish peroxidase–labeled secondary antibody
and then visualized using the ECL system (GE Healthcare Lifesciences,
Cleveland, Ohio). The band intensities were quantified by Image-J soft-
ware (Wine Rasband, Bethesda, Md). The values obtained were expressed
as a percentage of the value in the J2N-n hamsters.
Statistical Analysis
Data are summarized as means  SEMs. Comparisons among groups
weremadewith the use of 1-way analysis of variance, followed by theTukey
honestly significant difference test. Differences across thewhole time course
of echocardiographic data and the concentration ofONO1301were analyzed
by repeated analysis of variance including main effects of the group, time,
and their interactive effects, followed by pairwise comparisons at different
times using a paired t test with the Bonferroni multiplicity correction. Sur-
vival curveswere prepared by using theKaplan-Meiermethod and compared
using the log-rank test. All probability values are 2-sided. Statistical analysis
was performed by using SPSS version 11.0 (SPSS, Inc, Chicago, Ill).1518 The Journal of Thoracic and Cardiovascular SurRESULTS
Effects of ONO1301 on the Secretion of Protective
Factors in Vitro
Dose-dependent effects of ONO1301 on each component
of the cells were assessed by cultivating commercially avail-
able NHDFs, HCoASMCs in vitro. Synthesis and extracellu-
lar secretionof protective factorswere quantitatively assessed
by real-time PCR and enzyme-linked immunosorbent assay
(ELISA;Quantikine; R&DSystems,Minneapolis,Minn), re-
spectively. ONO1301 treatment upregulated the expressions
of HGF, VEGF, and stromal cell–derived factor-1 (SDF-1),
but not granulocyte colony stimulating factor (G-CSF), in
the NHDFs assessed by real-time PCR (Figure 1, A). In par-
ticular, a high concentration of ONO1301 significantly upre-
gulated expressions of these factors. These findings were
consistent with the results of ELISA for the culture superna-
tants (Figure 1, B). A high concentration of ONO1301 also
significantly upregulated expressions of HGF, VEGF, and
G-CSF, but not SDF-1, in the HCoASMCs, assessed by
real-time PCR and ELISA (Figure 1, C and D).
Heart-Dominant Elevation of ONO1301
Concentration After ONO1301 Treatment
The difference in the ONO1301 concentration between the
plasma and the LV after ONO1301 treatment was quantita-
tively and serially assessed by the LC/MS/MS method. The
ventricular ONO1301 concentration was markedly greater
than the plasma concentration at week 1 and week 2 after
the treatment, although the plasma ONO1301 concentrationgery c December 2013
Ishimaru et al Evolving Technology/Basic Sciencewas higher than the detectable limit for this period (Figure 2,
A). Both ventricular and plasma concentrations of ONO1301
were less than the detectable limit at weeks 4 and 8.Presence of IPR in the Vasculature of the IDCM
Heart
Localization of the IPR in the heart was assessed by im-
munohistolabeling. IPR was present in the microvascula-
ture component, such as vascular SMCs and endothelial
cells (Figure 2, B and C), but not in the cardiac fibroblasts
or cardiomyocytes (Figure 2, D). Expression of the IPR
was not different between the J2N-k and J2N-n hamsters.Preserved Cardiac Performance in the IDCM
Hamster With ONO1301 Therapy
The functional effects of ONO1301-atelocollagen sheet
implantation on the IDCM heart were serially assessed by
transthoracic echocardiography. LVDd/Ds and EF at 20
weeks of age, just before the treatment, were not signifi-
cantly different among the 3 groups (Figure 2, E). After
treatment, echocardiography showed that the LVDd/Ds
and EF were significantly preserved until 4 weeks in the
O group, compared with the N and S groups, which showed
a progressive increase of LVDd/Ds and a progressive reduc-
tion of LVEF for the subsequent 8 weeks. However, even the
O group showed progressively increased LVDd/Ds and
reduced LVEF in the subsequent 4 weeks.T
/B
SUpregulated HGF and VEGF in the Heart After
ONO1301 Treatment
Real-time PCRwas used to quantitatively assess the trend
in expression of angiogenic factors, such as HGF andVEGF,
in the hearts of the 3 groups and the normal hamster (n¼ 5,
each). Intramyocardial mRNA levels of HGF and VEGF in
the S and the N groups were not significantly different
from those in the normal hamster at 2 or 4 weeks (Figure 3,
A). In contrast, in theOgroup, bothHGFandVEGFwere sig-
nificantly upregulated at 2 weeks compared with the other
groups. VEGF significantly upregulated in the O group at 4
weeks, although the HGF level in theO groupwas not signif-
icantly different from that in the other groups at 4 weeks.EIncreased Vasculature in the Heart After ONO1301
Treatment
The trend in the distribution and the number of arterioles
and capillaries in the heart after ONO1301 treatment was
assessed by vWF-labeled sections of the 3 groups and nor-
mal hamsters (n ¼ 5, each). The number of vWF-positive
arterioles and capillaries was significantly less in the N
and the S groups than in the normal heart at 2 and 4 weeks.
In contrast, vWF-positive arterioles and capillaries were
homogeneously increased in the O group at 2 and 4 weeks
compared with the other groups (Figure 3, B; P<.05).The Journal of Thoracic and CarEffect of ONO1301 on Myocardial Fibrosis
The distribution and the quantity of interstitial collagen in
the heart afterONO1301 treatmentwas assessed by picrosirius
red–stained sections (n¼ 5, each). Interstitial collagenwas sig-
nificantly accumulated in the J2N-k hamsters, regardless of the
treatment, compared with the normal hamsters (Figure 3, C).
However, collagen accumulation was significantly less in the
O group than in the S and the N groups at 2 and 4 weeks.Reorganization of Cytoskeletal Proteins After
ONO1301 Treatment
The trend in the expression of a-sarcoglycan in the hearts
after ONO1301 treatment was comprehensively assessed by
immunohistolabeling, real-time PCR, and Western blotting
analysis (Figure 4,A-C).a-Sarcoglycanwas homogeneously
expressed around the cardiomyocytes of the normal hamster,
but it was rarely expressed in the heart of theNor S groups on
immunoconfocal microscopy. In contrast, a-sarcoglycan ex-
pression was greater in the O group than in the N and S
groups at 2 weeks, but not at 4 weeks. The mRNA of a-sar-
coglycan was significantly greater in the O group than in the
S and the N groups at 2 weeks, but not at 4 weeks. Consis-
tently, Western blotting analysis in the heart showed signifi-
cantly upregulated a-sarcoglycan expression at 2 weeks, but
not at 4 weeks in the O group, compared with the S and the N
groups. In addition, the trends in expressions of other cyto-
skeletal proteins, such as b-sarcoglycan and a-dystroglycan,
after the ONO1301 treatment were assessed by immunohis-
tolabeling and real-time PCR (Figure 4, D and E). b-Sarco-
glycan was rarely expressed in the J2N-k hamster heart
regardless of treatment, whereas expression of a-dystrogly-
can appeared to be greater in theOgroup than in the S and the
N groups, although there were no significant differences.Survival Benefit of ONO1301 Treatment in IDCM
No mortality or morbidity related to surgical procedure
was identified in any of the groups. Survival of J2N-k ham-
sters after treatment was then assessed using the Kaplan-
Meier method. Hamsters of the N and the S groups showed
similar progression to death, primarily owing to congestive
cardiac failure over the 4 weeks after treatment. In contrast,
survival of hamsters in the O group was significantly pro-
longed compared with that of the other groups (Figure 5).DISCUSSION
Summary of the Findings
In the present study, ONO1301 induced secretion of mul-
tiple cardiac protective factors such as HGF, VEGF, SDF-1,
and G-CSF from NHDFs and HCoASMCs in a dose-
dependent manner in vitro. Epicardial implantation of an
ONO1301-immersed atelocollagen sheet, which was devel-
oped as a slow-releasing drug delivery system, induced
heart-dominant elevation of ONO1301 for 2 weeks indiovascular Surgery c Volume 146, Number 6 1519
FIGURE 1. Effects of ONO1301 on the production of cardiac protective factors in NHDFs and HCoASMCs were assessed in vitro. ONO1301 treatment
significantly upregulates expressions of HGF, VEGF, and SDF-1 in NHDFs, assessed by real-time PCR (A). HGF, VEGF, and SDF-1, but not G-CSF, are
significantly secreted into the culture supernatant of NHDF after ONO1301 addition, measured by ELISA (B). ONO1301 addition significantly upregulates
expressions of HGF, VEGF, and G-CSF, but not SDF-1, in HCoASMCs, assessed by real-time PCR and ELISA (C and D). *P<.05 versus control (DMSO);
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=Ishimaru et al Evolving Technology/Basic Sciencethe d-sarcoglycan-deficient DCM hamsters. ONO1301-
atelocollagen sheet implantation significantly upregulated
expression of HGF, VEGF, increased vasculature, attenu-
ated fibrosis, and upregulated a-sarcoglycan in the myocar-
dium and, consequently, preserved cardiac performance and
prolonged survival in this hamster DCM model.E
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Sheet–Based Therapy for IDCM
This study identified cell-dependent and dose-dependent
effects of ONO1301 on the release of cardioprotective
factors. The cells that were activated by ONO1301
in vitro included skin fibroblasts and CoASMCs. In addi-
tion, IPR, which is the sole receptor of ONO1301, was
expressed in CoASMCs and endothelial cells, but not in
cardiomyocytes or cardiac fibroblasts. These findings sug-
gest that the target cells of ONO1301 may be the vascular
SMCs and endothelial cells in the cardiac tissue. Local
delivery of ONO1301 into the heart, directly targeting
cardiac SMCs and endothelial cells, would thereby theoret-
ically be useful in maximizing the therapeutic effects of
ONO1301. In fact, it was shown that the ONO1301-
immersed atelocollagen sheet implantation therapy in-
duced marked heart-dominant elevation of the ONO1301
level in association with significantly positive functional
effects, indicating rationale and feasibility of this treatment
in the IDCM heart. In addition, both the ONO1301 and the
atelocollagen sheet only groups did not produce
procedure-related mortality despite the deteriorated car-
diac function, suggesting the safety of this treatment for
IDCM heart.
There are other possible clinically relevant methods for
ONO1301 delivery to treat the DCM heart, such as injection
of intramyocardial microbeads, systemic intravenous/sub-
cutaneous injection, or oral intake. However, these methods
are theoretically limited by possible local damage and/or
poor efficiency in the drug delivery to the cardiac tissue9
compared with the atelocollagen sheet–based drug delivery
system as in this study. Intramyocardial injection of mi-
crobeads may also prove to be more efficacious, but further
studies will be required to establish the optimal delivery
methods of ONO1301 into the heart in preclinical and subse-
quent clinical studies.
Therapeutic Effects and Underlying Mechanisms of
ONO1301 Sheet Therapy
Therapeutic efficiency of this treatment on this d-sarco-
glycan-deficient hamster IDCM model was assured in thisyP<.05 versus ONO1301 (1 nmol/L); #P<.05 versus ONO1301 (10 nmol/L);
nmol/L). NHDF, Normal human dermal fibroblast; HCoASMC, human coronar
endothelial growth factor; SDF-1, stromal cell–derived factor-1; PCR, polymer
enzyme-linked immunosorbent assay; DMSO, dimethyl sulphoxide; cAMP, cyc
The Journal of Thoracic and Carstudy by comparing with the 2 control groups, in which
the sham operation or placement of atelocollagen sheet
only was performed. Global systolic cardiac function,
assessed by echocardiography, was significantly preserved
in the ONO1301-treated hamsters compared with the other
groups, and most important, the life expectancy of the
J2N-k hamsters was prolonged by this treatment. These im-
portant positive findings would be explained by multiple
fundamental effects of this treatment, including increased
myocardial blood flow, reduction of myocardial fibrosis,
and reorganization of cytoskeletal proteins.
It has been reported that ONO1301 acts as an inducer of
multiple cardioprotective factors in ischemic cardiac dis-
eases.5 Effects of ONO1301 on the IDCM heart, however,
are poorly understood. Although the clinical manifestations
of end-stage IDCMare similar to those of end-stage ischemic
cardiomyopathy, typical IDCM is characterized by
a decreased vascular network, increased fibrous components,
and decreased expression of cytoskeletal proteins in a global
and homogeneous manner.10,11 This study also identified
multiple endogenous factors upregulated by the ONO1301-
atelocollagen sheet, such as HGF, a unique growth factor
with antifibrosis and angiogenesis effects,8,12 or VEGF, an
important mediator of angiogenesis.4 In addition, SDF-1 or
G-CSF by the ONO1301 treatment in this study may have
contributed to therapeutic stem cell homing and activa-
tion.13,14 Further studies will be required to determine
whether these agents induce regenerative responses.
The potential effects of these endogenous factors were
well correlated with the pathologic changes in this study,
such as increased vasculature, attenuated fibrosis, or upregu-
lated a-sarcoglycan. Of them, increased blood flow may be
one of the major mechanisms responsible for the positive
therapeutic effects of the ONO1301 in this study. It has
been shown that prostacyclin and prostacyclin-inducing
HGF/VEGF bring a multiplier effect of vasodilation and
new vessel formation responsible to regional ischemic
insult.15,16 In addition, genetic deletion of IPR had an
important role on progression of cardiovascular disease.15
It is also interesting that cytoskeletal proteinswere remod-
eled by the ONO1301 treatment in this study. Immunohisto-
labeling in this study demonstrated the transient reexpression
of a-sarcoglycan and a-dystroglycan in the O group. It was
speculated that a-sarcoglycan can be recycled from the
plasma membrane differently from other sarcoglycans,17
and inhibition of Smad3 associated with transforming
growth factor b signal pathway suppressed by prostacyclin
or HGF, brings to a-sarcoglycan gene expression.18xP<.05 versus ONO1301 (100 nmol/L); zP<.05 versus ONO1301 (1000
y artery smooth muscle cell; HGF, hepatic growth factor; VEGF, vascular
ase chain reaction; G-CSF, granulocyte colony stimulating factor; ELISA,
lic aminophosphatase; n.s., not significant.
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FIGURE 2. Levels of ONO1301 in cardiac tissue and plasmawere serially quantified after implantation of ONO1301-eluted atelocollagen sheet for the DCM
heart (A).ONO1301 is detected in both samples for 2weeks after treatment,while the level ofONO1301 in theventricle is significantly andmarkedly higher than
in the plasmaatweeks 1 and 2 after the treatment. *P<.05 versus 8weeks; yP<.05 versus plasma concentration Immunofluorescence staining for IPR and alpha-
actin in theDCMheart shows that IPR ispositive in thevascular smoothmuscle cells and the endotherial cells (BandC).Green, Filamentous-actin; red, IPR;blue,
nuclei. 3,30-diaminobenzidine staining, which produces a brown color, shows that IPR is expressed in the microvasculature, but not in cardiac fibroblasts and
cardiomyocytes (arrowhead, cardiac fibroblast) (D). Changes in LVDd/Ds, and LVEF after treatment were seriallymeasured by transthoracic echocardiography
(E). These 4 parameters of the LVare preserved until 4 weeks after ONO1301 treatment comparedwith the other groups. However, ONO1301 treatment does not
arrest the progression in dilatation of the dimensions and deterioration of the EF in the subsequent 4 weeks. #P<.05 versus N and S group; *P<.05 versus
0 weeks.DCM, Dilated cardiomyopathy; LV, left ventricular (ventricle);Dd/Ds, diastolic/systolic dimensions; EF, ejection fraction; IPR, prostacyclin receptor.
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glycan, Kondoh and associates9 suggested that the recon-
struction of a-dystroglycan may occur because the
sarcoglycan might mask the matrix metalloproteinase cleav-
age site on dystroglycan and/or matrix metalloproteinase ac-
tivity might be inhibited by HGF. In addition, b-sarcoglycan
was rarely expressed after the ONO1301 treatment in our1522 The Journal of Thoracic and Cardiovascular Surstudy. Kawada and colleagues19 reported that both b- and
d-sarcoglycan were completely missing, but a- and g-sarco-
glycan were weakly expressed in the J2N-k hamster, and
transfer of the d-sarcoglycan gene could express not only
d- but the other 3 sarcoglycans. These findings might suggest
the limitation of this drug therapy for reorganization of cyto-
skeletal proteins, but Hack and coworkers20 reported that thegery c December 2013
FIGURE 3. Expressions of HGF and VEGF in the cardiac tissue were assessed by real-time PCR, which shows greater expression of the 2 factors in the
O group at 2 and 4weeks compared with the other groups (n¼ 5 for each group) (A). Capillary density in the hearts was assessed by immunohistolabeling for
vWF, which shows a greater number of capillaries in the ONO1301-treated hearts than in the other groups at 2 and 4 weeks (n ¼ 5 for each group) (B).
Interstitial fibrosis in the heart was assessed by picrosirius red staining, which shows less accumulation of fibrosis in the ONO1301-treated hearts than
in the other groups at 2 and 4 weeks (n ¼ 5 for each group) (C). *P<.05 versus O group. HGF, Hepatic growth factor; VEGF, vascular endothelial growth
factor; PCR, polymerase chain reaction. vWF, von Willebrand factor.
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Sexpression of sarcoglycans, even in small amounts, pre-
vented the damage of cardiomyocyte. Reorganization of a-
sarcoglycan by the ONO1301 therapy might thus contribute
to preserve cardiac function.
Although the level of prostacyclin in the heart in response
to the ONO1301 treatment was not investigated in this
study, it may be paradoxically elevated by the thromboxane
synthase inhibitory activity of the ONO1301 on the heart,21
possibly producing synergetic positive effects on the IDCM
heart. In addition, it is interesting to research the involve-
ment of the neurohormonal activations in the heart, such
as adrenergic system, plasma renin activity, or endothelin,
by the ONO1301 treatment.22The Journal of Thoracic and CarClinical Perspectives
The atelocollagen sheet–based local ONO1301 delivery
therapy globally reversed reduced vascular density, in-
creased fibrosis, and reduced cytoskeletal proteins in the
myocardium, all of which were the typical pathologic fea-
tures in the human IDCM heart,10,11 suggesting potential
therapeutic benefits of this treatment for IDCM in the
clinical scenario. In addition, safety of this treatment
shown in this study warrants further preclinical study,
including dose-response relation to explore minimum and
maximal effective dose of the ONO1301 in the ‘‘GLP’’ stan-
dard. A very narrow dose necessary to achieve a positive
response may prohibit this agent from clinical trials.diovascular Surgery c Volume 146, Number 6 1523
FIGURE 4. Expression of a-sarcoglycan, b-sarcoglycan, and a-dystoglycan in the heart after ONO1301 treatment was assessed by immunohistolabeling,
real-time PCR, and Western blot analysis. Immunohistolabeling shows that a-sarcoglycan is clearly expressed around the cardiomyocytes in the normal
hamsters, but not in the N or S group (A). Of note, a-sarcoglycan is expressed in the O group at 2 weeks but not at 4 weeks. Green, a-Sarcoglycan;
red, filamentous-actin; blue, nuclei. Quantitative real-time PCR shows a significantly greater expression of a-sarcoglycan in the O group than in the N
or S group at 2 weeks, but not at 4 weeks (n ¼ 5 for each group at each time point, *P<.05 vs O group) (B). Consistently, Western blot analysis and
the quantitative results of band intensities, which are expressed as a percentage of the value of the J2N-n hamsters, show significantly greater expression
of a-sarcoglycan in the O group than in the N or S group at 2 weeks, but not at 4 weeks (n ¼ 5 for each group at each time point, *P<.05 vs O group) (C).
Expression of b-sarcoglycan in the DCM hamsters is not detected even after ONO1301 treatment (D). Green, b-sarcoglycan; red, filamentous-actin; blue,
nuclei. a-Dystroglycan is rarely expressed in the N or S group, although its expression is upregulated in the O group (E). There are no significant differences
between the O group and the other groups at 2 weeks.Green, a-Dystroglycan; red, filamentous-actin; blue, nuclei. PCR, Polymerase chain reaction; n.s., not
significant.
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SRe-treatment of epicardial implantation of the sheet con-
taining ONO1301 might be technically challenging; how-
ever, technical modulation of microsphere generation,
such as gelatin hydrogel, might induce further develop-
ments to generate a longer-release drug-delivery system
than the method used in the present study.231524 The Journal of Thoracic and Cardiovascular SurStudy Limitations
This study was limited by use of a transgenic rodent
model. The d-sarcoglycan-deficient IDCM model used in
this study is not completely relevant to human IDCM that
shows a number of etiologic and pathologic variations.
However, positive functional and pathologic effectsgery c December 2013
FIGURE 5. Survival after treatment was assessed by the Kaplan-Meier
method. There is no significant difference between the N (n ¼ 11) and S
groups (n¼ 13), whereas the O group (n¼ 12) shows a significantly greater
survival than the other groups (*P<.05 vs S group; yP<.05 vs N group).
Ishimaru et al Evolving Technology/Basic Scienceassociated with upregulated protective factors would be suf-
ficient to prove the principal concept of this treatment.
Agents that are beneficial in these mutant hamsters may
not be beneficial in humans because the mechanisms re-
sponsible for the beneficial effects may be different in hu-
mans. However, further pathologic and functional studies
for human DCM heart samples, in comparison with the de-
ficient hamster, may be useful to strengthen the findings of
this study.
Poor availability of the antibodies and genome sequences
in the hamster limited in-depth evaluation of the mecha-
nisms responsible for this treatment, which is warranted
to be supplemented by murine IDCM model.24E
T
/B
SCONCLUSIONS
ONO1301 reorganized cytoskeletal proteins, especially
a-sarcoglycan, increased capillaries, and reduced fibrosis
through the upregulationof cardiac protective factors, leading
to functional recovery and prolonged survival in the d-sarco-
glycan-deficient IDCM hamster. A preclinical study to ex-
plore the optimal, clinically relevant protocol is warranted.
We thank Masako Yokoyama, Akima Harada, and Motoko
Shiozaki for their excellent technical assistance.References
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